Array BioPharma Inc.’s $259 Million Initial Public Offering

Ballard Spahr represented Array BioPharma Inc. (Nasdaq: ARRY), in the recent closing of a public offering by the biopharmaceutical company, which generated total gross proceeds of $258.75 million, before underwriting discounts and commissions and offering expenses.

Array BioPharma closed the underwritten public offering of 24,069,766 shares of the Boulder-based company’s common stock, which includes 3,139,534 shares of common stock issued upon the exercise in full of the option to purchase additional shares granted to the underwriters, at a public offering price of $10.75 per share.

The Ballard Spahr team on the transaction was led by Carin M. Cutler, a partner in the firm’s Boulder and Denver offices, and was assisted by Mehrnaz Jalali in the firm’s New York office.

J.P. Morgan Securities, LLC, and Cowen and Company, LLC, acted as joint book-running managers for the offering. Piper Jaffray & Co. also acted as a book runner for the offering. Stifel and Wells Fargo Securities, LLC, acted as lead managers, and SunTrust Robinson Humphrey, Inc., acted as co-manager.

The shares were sold pursuant to an effective shelf registration statement filed with the Securities and Exchange Commission.

Array focuses on the discovery, development, and commercialization of targeted small-molecule drugs to treat cancer patients.

Ballard Spahr represented Array BioPharma Inc. with a team including Carin M. Cutler (Picture) and Mehrnaz Jalali


Involved fees earner: Carin Cutler – Ballard Spahr Stillman & Friedman LLP; Mehrnaz Jalali – Ballard Spahr Stillman & Friedman LLP;

Law Firms: Ballard Spahr Stillman & Friedman LLP;

Clients: Array BioPharma Inc.;



Author: Ambrogio Visconti